Alexandre Oliny
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandre Oliny has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Antoine Millon
7 shared publications- Marine Bordet
Department of Vascular and Endovascular Surgery, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
5 shared publications Matthieu Arsicot
Department of Vascular and Endovascular Surgery, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France
4 shared publicationsNellie Della Schiava
4 shared publicationsDominique Fabre
Department of Vascular Surgery, Aortic Center, Hôpital Marie Lannelongue, Groupe hospitalier Paris Saint Joseph, INSERM UMR_S 999, Université Paris-Saclay, Paris, France
2 shared publications- Dominique Fabre
Paris-Saclay University, Marie Lannelongue Hospital, Le Plessis-Robinson, France
2 shared publications
Latest Publications
- Open Access
- 13 September 2026
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 15 (1)
Midterm outcomes after delayed first rib resection for acute axillosubclavian deep vein thrombosis in Paget-Schroetter syndrome
- 13 September 2026
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 15 (1)
Open AccessMidterm outcomes after delayed first rib resection for acute axillosubclavian deep vein thrombosis in Paget-Schroetter syndrome
- 16 January 2026
- Published by SAGE Publications in Journal of Endovascular Therapy
Mid-term Results of the Anaconda Fenestrated Stent-Graft Proximal Sealing System in the Exclusion of Complex Abdominal Aortic Aneurysms
Context: Mid-term data on the Anaconda fenestrated stent-graft remain scarce in the literature. Objective: The aim of this study was to evaluate the efficacy and durability of its Z-stent-free proximal sealing system. Methods: All consecutive patients treated between January 2018 and May 2023 with the Anaconda Fenestrated stent-graft (Vascutek/Terumo, Scotland, UK) for complex abdominal aortic aneurysm (AAA) were retrospectively included in this monocentric study. The primary outcome was the occurrence of type Ia endoleak (EL). The secondary outcome was the evolution of the proximal sealing zone (PSZ), defined as proximal neck dilatation (PND) ≥3 mm, stent-graft migration (>10 mm), or the need for PSZ-related reintervention. Effective oversizing (OS) was calculated from the nominal stent-graft diameter and the mean aortic diameter at the PNR level on postoperative computed angiography (CT) angiography. Results: A total of 111 patients were included (mean age 72±7.6 years, 86% male) with 69 juxta renal aneurysms (62.2%), 23 para-renal aneurysms (20.7%), and 19 proximal EL after EVAR (17.1%). The mean follow-up was 28.1±16.2 months. No primary type Ia EL was observed at discharge. During follow-up, 1 patient (<1%) developed a secondary type Ia EL, which was successfully managed with the placement of an aortic cuff. The PND was observed in 40 patients (36%), while significant stent-graft migration was observed in 1 patient (0.9%) without any impact on proximal sealing or bridging-stents. Effective OS was the only independent predictor of PND in the multivariable analysis (odds ratio [OR]=1.193; 95% confidence interval [CI]= 1.104-1.288; p<0.001). Seven patients (6.3%) underwent prophylactic PSZ-related reintervention, at a mean interval of 26.4±16.9 months following the index procedure, to prevent the occurrence of a type Ia EL. Conclusion: The proximal sealing system of the Anaconda fenestrated stent-graft’s demonstrates encouraging mid-term performance, with a low incidence of type Ia EL observed over more than 2 years of follow-up. The PND related to stent-graft OS is common but generally stabilizes after the first year. Beyond this point, any progression should be attributed to the underlying aortic disease. In such cases, proximal extension of the sealing zone can be performed with satisfactory outcomes. Clinical Impact: This study provides the first dedicated mid-term evaluation of the proximal sealing system of the Anaconda® fenestrated stent-graft in complex abdominal aortic aneurysms. When implanted in a healthy supraceliac landing zone with adequate effective oversizing, the device offers durable proximal sealing with a low incidence of type Ia endoleak. These findings support confident use of the Anaconda® platform in challenging anatomies, while emphasizing the importance of careful deployment to avoid use of the repositioning system and the associated risk of ring tilting. The study also highlights that early proximal neck dilatation is common but usually stabilizes, justifying tailored surveillance and allowing prophylactic proximal extension when necessary.
- 16 January 2026
- Published by SAGE Publications in Journal of Endovascular Therapy
Mid-term Results of the Anaconda Fenestrated Stent-Graft Proximal Sealing System in the Exclusion of Complex Abdominal Aortic Aneurysms
Context: Mid-term data on the Anaconda fenestrated stent-graft remain scarce in the literature. Objective: The aim of this study was to evaluate the efficacy and durability of its Z-stent-free proximal sealing system. Methods: All consecutive patients treated between January 2018 and May 2023 with the Anaconda Fenestrated stent-graft (Vascutek/Terumo, Scotland, UK) for complex abdominal aortic aneurysm (AAA) were retrospectively included in this monocentric study. The primary outcome was the occurrence of type Ia endoleak (EL). The secondary outcome was the evolution of the proximal sealing zone (PSZ), defined as proximal neck dilatation (PND) ≥3 mm, stent-graft migration (>10 mm), or the need for PSZ-related reintervention. Effective oversizing (OS) was calculated from the nominal stent-graft diameter and the mean aortic diameter at the PNR level on postoperative computed angiography (CT) angiography. Results: A total of 111 patients were included (mean age 72±7.6 years, 86% male) with 69 juxta renal aneurysms (62.2%), 23 para-renal aneurysms (20.7%), and 19 proximal EL after EVAR (17.1%). The mean follow-up was 28.1±16.2 months. No primary type Ia EL was observed at discharge. During follow-up, 1 patient (<1%) developed a secondary type Ia EL, which was successfully managed with the placement of an aortic cuff. The PND was observed in 40 patients (36%), while significant stent-graft migration was observed in 1 patient (0.9%) without any impact on proximal sealing or bridging-stents. Effective OS was the only independent predictor of PND in the multivariable analysis (odds ratio [OR]=1.193; 95% confidence interval [CI]= 1.104-1.288; p<0.001). Seven patients (6.3%) underwent prophylactic PSZ-related reintervention, at a mean interval of 26.4±16.9 months following the index procedure, to prevent the occurrence of a type Ia EL. Conclusion: The proximal sealing system of the Anaconda fenestrated stent-graft’s demonstrates encouraging mid-term performance, with a low incidence of type Ia EL observed over more than 2 years of follow-up. The PND related to stent-graft OS is common but generally stabilizes after the first year. Beyond this point, any progression should be attributed to the underlying aortic disease. In such cases, proximal extension of the sealing zone can be performed with satisfactory outcomes. Clinical Impact: This study provides the first dedicated mid-term evaluation of the proximal sealing system of the Anaconda® fenestrated stent-graft in complex abdominal aortic aneurysms. When implanted in a healthy supraceliac landing zone with adequate effective oversizing, the device offers durable proximal sealing with a low incidence of type Ia endoleak. These findings support confident use of the Anaconda® platform in challenging anatomies, while emphasizing the importance of careful deployment to avoid use of the repositioning system and the associated risk of ring tilting. The study also highlights that early proximal neck dilatation is common but usually stabilizes, justifying tailored surveillance and allowing prophylactic proximal extension when necessary.
- 7 November 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (5) , 2729-2738
Mid-Term Results of an Unsupported Body Fenestrated Graft for Treating Thoracoabdominal and Suprarenal Aneurysms
Purpose: To evaluate the safety and efficacy of a strategy using the Anaconda Fenestrated endograft for treating thoracoabdominal aortic aneurysms (TAA) and supra-renal aortic aneurysms (SRAAs). Methods: Patients electively treated with the Anaconda Fenestrated endograft for an unruptured TAA or SRAA at our center between 2018 and 2023 were retrospectively analyzed. The treatment strategy included staged procedures prior to fenestrated endovascular aneurysm repair (FEVAR) and implantation of the Anaconda graft into thoracic grafts for TAA and for SRAA with an unfavorable proximal landing zone. Primary outcome was survival. Secondary outcomes included technical and early clinical success, target-vessel patency (TVP), freedom from reintervention, sac evolution, target-vessel instability (TVI), and endoleaks. Results: A total of 57 patients (72% male, median age 70 years) were included, comprising 32 (56.1%) SRAA and 25 (43.9%) TAA. Nineteen patients (33.3%) underwent staged procedures, and technical success was 94.7%. There were 3 (5.3%) early deaths, 1 (1.8%) permanent paraplegia, and 1 (1.8%) type IIIc endoleak, leading to an early clinical success rate of 93.0%. The mean follow-up duration was 31.6 ± 19.7 months for mortality, and 28 ± 17.0 months for other outcomes. A total of 12 (21.1%) deaths were recorded, including 4 aneurysm-related deaths, resulting in 1-year and 4-year overall survival rates of 87.7% and 78.1%, respectively. The primary TVP rate was 95.9% at 1 year and 95.2% at 5 years, while the 1-year and 3-year freedom from TVI was 84.7% and 72.2%, respectively. Seventeen patients (29.8%) required early (n=7) or late (n=14) reinterventions, resulting in 1-year and 3-year freedom from reintervention of 76.1% and 61.1%, respectively. One type 1a (1.8%), 1 type 1b (1.8%), and 5 type 3c (8.8%) endoleaks were identified and treated during follow-up. Aneurysm growth (>5 mm) was observed in 2 patients (3.8%), while sac shrinkage (>5 mm) was achieved in 29 patients (55.8%). Conclusion: This study demonstrates that a strategy using the Anaconda Fenestrated endograft provides acceptable efficacy and safety in the treatment of SRAA and TAA. Despite a high reintervention rate, mid-term survival, and target-vessel patency support the use of this endograft as a valid treatment option for these aneurysms. Clinical Impact: This study reports the outcomes of 57 patients treated for suprarenal and thoracoabdominal aneurysms using the Anaconda unsupported fenestrated stent graft, combined with thoracic modules when necessary. Mid-term survival and target vessel patency were acceptable, with no indication of inferior performance compared to established platforms. While the reintervention rate warrants caution, these findings support the Anaconda fenestrated system as a potential alternative for complex aneurysms. Larger studies with extended follow-up are needed to better identify patients who may benefit from an unsupported design and to confirm its long-term durability.
- 7 November 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (5) , 2729-2738
Mid-Term Results of an Unsupported Body Fenestrated Graft for Treating Thoracoabdominal and Suprarenal Aneurysms
Purpose: To evaluate the safety and efficacy of a strategy using the Anaconda Fenestrated endograft for treating thoracoabdominal aortic aneurysms (TAA) and supra-renal aortic aneurysms (SRAAs). Methods: Patients electively treated with the Anaconda Fenestrated endograft for an unruptured TAA or SRAA at our center between 2018 and 2023 were retrospectively analyzed. The treatment strategy included staged procedures prior to fenestrated endovascular aneurysm repair (FEVAR) and implantation of the Anaconda graft into thoracic grafts for TAA and for SRAA with an unfavorable proximal landing zone. Primary outcome was survival. Secondary outcomes included technical and early clinical success, target-vessel patency (TVP), freedom from reintervention, sac evolution, target-vessel instability (TVI), and endoleaks. Results: A total of 57 patients (72% male, median age 70 years) were included, comprising 32 (56.1%) SRAA and 25 (43.9%) TAA. Nineteen patients (33.3%) underwent staged procedures, and technical success was 94.7%. There were 3 (5.3%) early deaths, 1 (1.8%) permanent paraplegia, and 1 (1.8%) type IIIc endoleak, leading to an early clinical success rate of 93.0%. The mean follow-up duration was 31.6 ± 19.7 months for mortality, and 28 ± 17.0 months for other outcomes. A total of 12 (21.1%) deaths were recorded, including 4 aneurysm-related deaths, resulting in 1-year and 4-year overall survival rates of 87.7% and 78.1%, respectively. The primary TVP rate was 95.9% at 1 year and 95.2% at 5 years, while the 1-year and 3-year freedom from TVI was 84.7% and 72.2%, respectively. Seventeen patients (29.8%) required early (n=7) or late (n=14) reinterventions, resulting in 1-year and 3-year freedom from reintervention of 76.1% and 61.1%, respectively. One type 1a (1.8%), 1 type 1b (1.8%), and 5 type 3c (8.8%) endoleaks were identified and treated during follow-up. Aneurysm growth (>5 mm) was observed in 2 patients (3.8%), while sac shrinkage (>5 mm) was achieved in 29 patients (55.8%). Conclusion: This study demonstrates that a strategy using the Anaconda Fenestrated endograft provides acceptable efficacy and safety in the treatment of SRAA and TAA. Despite a high reintervention rate, mid-term survival, and target-vessel patency support the use of this endograft as a valid treatment option for these aneurysms. Clinical Impact: This study reports the outcomes of 57 patients treated for suprarenal and thoracoabdominal aneurysms using the Anaconda unsupported fenestrated stent graft, combined with thoracic modules when necessary. Mid-term survival and target vessel patency were acceptable, with no indication of inferior performance compared to established platforms. While the reintervention rate warrants caution, these findings support the Anaconda fenestrated system as a potential alternative for complex aneurysms. Larger studies with extended follow-up are needed to better identify patients who may benefit from an unsupported design and to confirm its long-term durability.
- Open Access
- 9 September 2025
- Published by Elsevier in EJVES Vascular Forum
- Vol. 64, 146-153
Midterm Aortic Neck Evolution after EndoSuture Aneurysm Repair: a Single Centre Retrospective Analysis
- 9 September 2025
- Published by Elsevier in EJVES Vascular Forum
- Vol. 64, 146-153
Open AccessMidterm Aortic Neck Evolution after EndoSuture Aneurysm Repair: a Single Centre Retrospective Analysis
- 26 August 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (2) , 394-403
Impact of a new stepped balloon for bridging stent implantation on procedural time and radiation exposure in fenestrated endovascular aortic repair
- 26 August 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (2) , 394-403
Impact of a new stepped balloon for bridging stent implantation on procedural time and radiation exposure in fenestrated endovascular aortic repair
- Open Access
- 30 March 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 70 (3) , 326-334
Midterm Outcomes of the Fenestrated Anaconda Stent Graft for Complex Aortic Aneurysm Repair: A Large, Single Centre, Retrospective Study
- 30 March 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 70 (3) , 326-334
Open AccessMidterm Outcomes of the Fenestrated Anaconda Stent Graft for Complex Aortic Aneurysm Repair: A Large, Single Centre, Retrospective Study
- 27 January 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (6) , 910-918
Pre-clinical Evaluation of a New Generation Bridging Stent for Fenestrated Endovascular Aneurysm Repair Using Realistic 3D Printed Aneurysm Models
- 27 January 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (6) , 910-918
Pre-clinical Evaluation of a New Generation Bridging Stent for Fenestrated Endovascular Aneurysm Repair Using Realistic 3D Printed Aneurysm Models
- 26 September 2024
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (2) , 844-852
Fenestrated Endovascular Aortic Repair of Complex Aneurysm Using the Anaconda Fenestrated Device: 1-Year Results From the French Multicenter Registry
Purpose: This study aims to assess the safety and efficacy of the fenestrated Anaconda device for the treatment of complex aortic aneurysms over 1 year in daily clinical practice. Materials and Methods: All patients who received the graft between October 2019 and October 2020 were prospectively enrolled in an observational, multicenter national registry. The primary endpoint was the aneurysm-related 1-year mortality rate. Secondary endpoints included all-cause mortality, technical success, device-related adverse events (AEs) and major complications, secondary reinterventions, endoleaks, target vessel (TV) outcomes, and a center-volume analysis comparing mortality and secondary reintervention rate between expert centers (>15 F/BEVAR per year) and nonexpert centers (≤15 F/BEVAR per year). Results: Ninety-seven patients from 28 centers were treated. Aneurysms types included juxta-renal and short neck (84.6%), pararenal (5.2%), paravisceral (3.1%), and type IV thoracoabdominal (2.5%). Configurations with 1, 2, 3, and 4 fenestrations were used in 2, 12, 18, and 65 cases, respectively, totaling 350 TVs. Technical success was 98.0%, with 1 type Ic and 1 type IIIc endoleak. Mean follow-up was 468 days. Ten patients died, with 8 deaths (8.2%) due to non-aortic causes and 2 deaths (2.1%) from unknown causes. The estimated 1-year survival rate was 92.7% (95% CI: 87.8-98.1%). The reintervention rate at 30 days was 11.3% and the estimated reintervention rate at 1 year was 21.6% (95% CI: 12.7-29.6%). No type Ia endoleak occurred during follow-up. Three type III endoleaks occurred and required reintervention. Three TV occlusion occurred, yielding a 1-year TVI-free rate of 92.4% (95% CI: 89.4-99.3). No device-related major complication was recorded, and 3 device-related AEs occurred: 1 limb migration, 1 limb kinking and 1 limb thrombosis. There was no statistically significant difference in mortality and survival without reintervention between expert and nonexpert centers (Log rank p=0.52 and p=0.16, respectively). Conclusion: The fenestrated Anaconda device demonstrated acceptable early and at 1-year safety and efficacy for treating primarily juxta-renal and short-neck aortic aneurysms, in centers with varying levels of experience. Clinical Impact: The Anaconda Fenestrated, as the second commercially available custom-made device for complex endovascular aortic surgery, might adress some anatomical challenges. Following market authorization, this registry presents the 1-year outcomes of real-world device usage in a large number of centers, including small clinics. The results indicate that the device provided adequate efficacy and safety for treating mostly juxta-renal and short neck aneurysms, with notable improvement in technical success rate compared to older reports.
- 26 September 2024
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (2) , 844-852
Fenestrated Endovascular Aortic Repair of Complex Aneurysm Using the Anaconda Fenestrated Device: 1-Year Results From the French Multicenter Registry
Purpose: This study aims to assess the safety and efficacy of the fenestrated Anaconda device for the treatment of complex aortic aneurysms over 1 year in daily clinical practice. Materials and Methods: All patients who received the graft between October 2019 and October 2020 were prospectively enrolled in an observational, multicenter national registry. The primary endpoint was the aneurysm-related 1-year mortality rate. Secondary endpoints included all-cause mortality, technical success, device-related adverse events (AEs) and major complications, secondary reinterventions, endoleaks, target vessel (TV) outcomes, and a center-volume analysis comparing mortality and secondary reintervention rate between expert centers (>15 F/BEVAR per year) and nonexpert centers (≤15 F/BEVAR per year). Results: Ninety-seven patients from 28 centers were treated. Aneurysms types included juxta-renal and short neck (84.6%), pararenal (5.2%), paravisceral (3.1%), and type IV thoracoabdominal (2.5%). Configurations with 1, 2, 3, and 4 fenestrations were used in 2, 12, 18, and 65 cases, respectively, totaling 350 TVs. Technical success was 98.0%, with 1 type Ic and 1 type IIIc endoleak. Mean follow-up was 468 days. Ten patients died, with 8 deaths (8.2%) due to non-aortic causes and 2 deaths (2.1%) from unknown causes. The estimated 1-year survival rate was 92.7% (95% CI: 87.8-98.1%). The reintervention rate at 30 days was 11.3% and the estimated reintervention rate at 1 year was 21.6% (95% CI: 12.7-29.6%). No type Ia endoleak occurred during follow-up. Three type III endoleaks occurred and required reintervention. Three TV occlusion occurred, yielding a 1-year TVI-free rate of 92.4% (95% CI: 89.4-99.3). No device-related major complication was recorded, and 3 device-related AEs occurred: 1 limb migration, 1 limb kinking and 1 limb thrombosis. There was no statistically significant difference in mortality and survival without reintervention between expert and nonexpert centers (Log rank p=0.52 and p=0.16, respectively). Conclusion: The fenestrated Anaconda device demonstrated acceptable early and at 1-year safety and efficacy for treating primarily juxta-renal and short-neck aortic aneurysms, in centers with varying levels of experience. Clinical Impact: The Anaconda Fenestrated, as the second commercially available custom-made device for complex endovascular aortic surgery, might adress some anatomical challenges. Following market authorization, this registry presents the 1-year outcomes of real-world device usage in a large number of centers, including small clinics. The results indicate that the device provided adequate efficacy and safety for treating mostly juxta-renal and short neck aneurysms, with notable improvement in technical success rate compared to older reports.
- Open Access
- 13 May 2024
- Published by Elsevier in EJVES Vascular Forum
- Vol. 61, 113-115
Closure Device Migration: An Unusual Cause of Acute Limb Ischaemia Following a Simple Endovascular Procedure
- 13 May 2024
- Published by Elsevier in EJVES Vascular Forum
- Vol. 61, 113-115
Open AccessClosure Device Migration: An Unusual Cause of Acute Limb Ischaemia Following a Simple Endovascular Procedure
- Open Access
- 16 December 2023
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 10 (2) , 101400
Thoracic outlet syndrome: single-center experience on the transaxillary approach with the aid of the TRIMANO Arthrex arm
- 16 December 2023
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 10 (2) , 101400
Open AccessThoracic outlet syndrome: single-center experience on the transaxillary approach with the aid of the TRIMANO Arthrex arm